AstraZeneca’s Truqap Wins FDA Panel Backing in Prostate Cancer

sciencepharma 2 posts · 2 accounts

AstraZeneca’s Truqap was recommended by an FDA advisory committee for the treatment of PTEN-deficient prostate cancer, with the panel voting 7-1 in favor of the combination treatment.

From the sources (2 posts)

@firstsquawk

ASTRAZENECA: TRUQAP HAS BEEN RECOMMENDED BY THE FDA ADVISORY COMMITTEE FOR THE TREATMENT OF PTEN-DEFICIENT PROSTATE CANCER, WITH THE COMMITTEE VOTING 7-1 IN FAVOR OF THE COMBINATION TREATMENT.

@13f_pro

@FirstSquawk 7-1 committee vote on a PTEN-deficient prostate cancer combo is a clean regulatory path. AZN's already got Calquence in the arsenal—if TRUQAP approval lands by summer, that's a new revenue stream in a patient segment with limit

Estée Lauder Raises Profit Forecast, Expands Job Cuts to 10,000 Samsung Foundry 4nm Yield Tops 80% as Orders Rise